Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
about
Cracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and PerspectivesTherapy-Related Myeloid NeoplasmsTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell ActivityEvaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Preleukemia: one name, many meanings.Therapy-related myeloid neoplasms: when genetics and environment collide.Myelodysplastic Syndromes: Updates and Nuances.Evolving role of FNA biopsy in diagnosing lymphoma: past, present, and future.TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaFavorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.Bone marrow findings in blast phase of polycythemia vera.Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
P2860
Q26776038-A4A5A284-B41E-4E1A-A789-6086062F2720Q26799786-5286C1D0-235C-4257-AFE9-09D69499B1A9Q35606212-9D4B1633-42A7-475E-AAFA-BE733E43E1D2Q36080036-71379178-6149-42D9-8890-BB9ECCFB4DF4Q37047952-65A013C9-0370-4A9D-9928-EE8860A32672Q37624593-E27441A9-63EC-471E-951C-0C6906BCA862Q37683379-4CE19331-E5AB-45CC-BF7A-3FBB29AC68BDQ38611096-07D8C1CB-3047-468D-8FB3-82FA15D7DED6Q38965973-56AC0CEF-87F1-4760-A684-C0914E83C196Q39012879-F9D02BCD-59C1-4317-9778-277BFCC9FE78Q39555179-F6B7302C-0624-49F1-A3D8-E1CF496FF5F3Q39575152-30BD30B5-4E5F-4AAA-8730-53A0DED7F920Q41264435-B3B2A78F-43AB-4013-8F1B-1931EDD41589Q47158332-1A4273F1-6A57-4D86-95C5-F22612EDA851Q49504954-10F633DC-6A36-4193-9556-4895602CEAD4Q53412376-C95DE96F-2333-409E-B756-7D9FE3111BA9Q53459692-163E1F99-4ECE-4B97-8D82-2847F243F120Q53479508-698872ED-4C05-4BF1-93AE-0EBF6608DE48Q55120146-30D117B0-3C15-4EA8-96A4-9E07E19D6746
P2860
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Mutational profiling of therap ...... parison with de novo diseases.
@en
type
label
Mutational profiling of therap ...... parison with de novo diseases.
@en
prefLabel
Mutational profiling of therap ...... parison with de novo diseases.
@en
P2093
P2860
P1433
P1476
Mutational profiling of therap ...... parison with de novo diseases.
@en
P2093
Chi Young Ok
Guilin Tang
Ken H Young
Keyur P Patel
L Jeffrey Medeiros
Maitrayee Goswami
Mark J Routbort
Rajesh Singh
Rajyalakshmi Luthra
P2860
P304
P356
10.1016/J.LEUKRES.2014.12.006
P577
2014-12-20T00:00:00Z